Dorsomedial hypothalamic corticotropin-releasing factor mediation of exercise-induced anorexia.
Running wheel access and resulting voluntary exercise alter food intake and reduce body weight. The neural mechanisms underlying these effects are unclear. In this study, we first assessed the effects of 7 days of running wheel access on food intake, body weight, and hypothalamic gene expression. We demonstrate that running wheel access significantly decreases food intake and body weight and results in a significant elevation of CRF mRNA expression in the dorsomedial hypothalamus (DMH) but not the paraventricular nucleus. Seven-day running wheel access also results in elevated arcuate nucleus and DMH neuropeptide Y gene expression. To assess a potential role for elevated DMH CRF activity in the activity-induced changes in food intake and body weight, we compared changes in food intake, body weight, and hypothalamic gene expression in rats receiving intracerebroventricular (ICV) CRF antagonist alpha-helical CRF or vehicle with or without access to running wheels. During a 4-day period of running wheel access, we found that exercise-induced reductions of food intake and body weight were significantly attenuated by ICV injection of the CRF antagonist. The effect on food intake was specific to a blockade of activity-induced changes in meal size. Central CRF antagonist injection further increased DMH CRF mRNA expression in exercised rats. Together, these data suggest that DMH CRF play a critical role in the anorexia resulting from increased voluntary exercise.
Kawaguchi
Maiko
M
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 720 Rutland Ave., Ross 618, Baltimore, MD 21205, USA.
Scott
Karen A
KA
Moran
Timothy H
TH
Bi
Sheng
S
D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004302:Dorsomedial Hypothalamic Nucleus / Q000502:physiology*; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D004734:Energy Metabolism / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology; D017403:In Situ Hybridization; D007267:Injections; D007276:Injections, Intraventricular; D008297:Male; D010286:Paraventricular Hypothalamic Nucleus / Q000502:physiology; D010446:Peptide Fragments / Q000494:pharmacology; D005082:Physical Exertion / Q000502:physiology*; D015347:RNA Probes; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley
D006727:Hormone Antagonists; D010446:Peptide Fragments; D015347:RNA Probes; D012333:RNA, Messenger; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41)